GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Institutional Ownership

NRX Pharmaceuticals (STU:B1Q) Institutional Ownership : 3.66% (As of Jun. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NRX Pharmaceuticals's institutional ownership is 3.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NRX Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NRX Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 70.55%.


NRX Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for NRX Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Institutional Ownership Chart

NRX Pharmaceuticals Historical Data

The historical data trend for NRX Pharmaceuticals can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 4.86 4.84 4.64 4.63 3.95 4.10 4.14 4.36 4.05 3.66

NRX Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


NRX Pharmaceuticals (STU:B1Q) Business Description

Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines